The Effect of Helminths on Granulocyte Activation: A Cluster-Randomized Placebo-Controlled Trial in Indonesia

Karin de Ruiter,^{1,2} Dicky L. Tahapary,^{1,3} Erliyani Sartono,¹ Thomas B. Nutman,⁵ Johannes W.A. Smit,^{6,2} Leo Koenderman,^{7,8} Taniawati Supali,⁴ and Maria Yazdanbakhsh¹

¹Department of Parasitology, and ²Department of Internal Medicine, Leiden University Medical Center, The Netherlands; ³Department of Internal Medicine, Division of Endocrinology and Metabolism, Dr. Cipto Mangunkusumo National General Hospital, and ⁴Department of Parasitology, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; ⁵Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland; ⁶Department of Internal Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands; ⁷Laboratory of Translational Immunology, and ⁸Department of Respiratory Medicine, University Medical Center Utrecht, The Netherlands

Background. Eosinophils are a prominent cell type in the host response to helminths, and some evidence suggests that neutrophils might also play a role. However, little is known about the activation status of these granulocytes during helminth infection.

Methods. We analyzed the expression of eosinophil and neutrophil activation markers in peripheral blood by flow cytometry and measured serum levels of eosinophil granule proteins in 300 subjects residing in an area endemic for soil-transmitted helminths (STH). The data generated are on samples before and after 1 year of 3-monthly albendazole treatment.

Results. Anthelmintic treatment significantly reduced the prevalence of STH. While eosinophil numbers were significantly higher in STH-infected compared to uninfected subjects and significantly decreased following albendazole treatment, there was no effect exerted by the helminths on either eosinophil nor neutrophil activation. Although at baseline eosinophil granule protein levels were not different between STH-infected and uninfected subjects, treatment significantly reduced the levels of eosinophil-derived neurotoxin (EDN) in those infected at baseline.

Conclusions. These results show that besides decreasing eosinophil numbers, anthelmintic treatment does not significantly change the activation status of eosinophils, nor of neutrophils, and the only effect seen was a reduction in circulating levels of EDN.

Clinical Trials Registration. <http://www.isrctn.com/ISRCTN75636394>

Keywords. eosinophils; neutrophils; helminths; granular proteins; activation markers; Indonesia.

Eosinophilia is a well-known hallmark of helminth infections. While these bone marrow-derived, innate cells reside primarily in the tissues where they can survive up to 2 weeks [1], elevated frequencies are found in peripheral blood during helminth infections and, to a lesser extent, in allergic diseases. Although eosinophils have been shown to be able to kill helminths in vitro [2–5], their role during helminth infections remains uncertain, as in vivo depletion of eosinophils has shown inconclusive results regarding their protective efficacy [6], and helminths such as *Trichinella* larvae, appear to benefit from the presence of eosinophils [7, 8]. Furthermore, eosinophils are increasingly recognized as cells that contribute to tissue, metabolic, and immune homeostasis [9]. Adipose tissue eosinophils for example, play a crucial role in maintaining insulin sensitivity through the secretion of the cytokines interleukin-4 (IL-4) and IL-13 [10].

Whereas increased eosinophil concentrations are characteristic of helminth infections, it is the activation status of these cells that drives the eosinophil-mediated effects [11]. Eosinophils can exist in different states of activation, reflected by the expression of certain surface markers and by the increased serum levels of eosinophil-specific granule proteins. Upon recruitment to inflammatory sites, eosinophils alter the expression of a number of surface molecules that are involved in tethering, rolling along, and adhesion to endothelial cells, followed by transendothelial migration into the tissue [12]. The presence of these surface molecules (for example CD11b, CD35, CD69, CD66b, and CD62L) on peripheral blood eosinophils is a useful indicator of cellular activation, during both helminth infections [13–15] and allergic diseases [16–19]. Moreover, eosinophils respond to eotaxin, a chemokine responsible for eosinophil recruitment into tissues, by upregulating CD11b and shedding CD62L [20, 21].

Upon eosinophil degranulation, cytotoxic proteins, including major basic protein (MBP), eosinophil cationic protein (ECP), eosinophil-derived neurotoxin (EDN), and eosinophil peroxidase (EPO), are released from secondary granules, and increased serum levels of these granule proteins are also considered to be a measure of eosinophil activation [19].

Received 23 August 2018; editorial decision 8 November 2018; accepted 14 November 2018; published online November 17, 2018.

Correspondence: M. Yazdanbakhsh, Prof, Dr, Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands (m.yazdanbakhsh@lumc.nl).

The Journal of Infectious Diseases® 2019;219:1474–82

© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. DOI: 10.1093/infdis/jiy665

While neutrophils are known primarily for their potent antibacterial properties, they have also been shown to kill helminth larvae [22–24], and their granule protein myeloperoxidase was significantly elevated in subjects infected with *Strongyloides stercoralis* [25], indicating that neutrophils can also become activated during helminth infections. Similar to eosinophils, neutrophil activation is associated with the upregulation of several surface molecules, including CD11b, CD35, and CD66b, and the shedding of CD62L [16, 18]. Although the expression of these markers and their upregulation or shedding in response to *N*-formyl-Met-Leu-Phe (fMLF) have been used as a very sensitive measure of neutrophil (pre-)activation in patients with allergic asthma [16–18], it has never been studied in the context of helminth infections.

In this study, we assessed the effect of helminth infections on the activation status and responsiveness of both eosinophils and neutrophils. Although previous work has shown that helminth infections are associated with increased eosinophil activation by assessing either activation markers [13–15] or eosinophil granule proteins [11, 25–28], these studies often had a cross-sectional design, a relatively small sample size, and did not assess eosinophil responsiveness. To this end, we measured the expression of eosinophil and neutrophil activation markers by flow cytometry, both *ex vivo* and after *in vitro* stimulation, in subjects infected with soil-transmitted helminths (STH), before and after 1 year of anthelmintic treatment. In addition, serum levels of eosinophil granule proteins were assessed. This study is part of a large cluster-randomized, placebo-controlled trial [29] and therefore the first placebo-controlled trial investigating the effect of helminths on granulocyte activation.

METHODS

Study Design

This report describes a nested study within the SugarSPIN trial [29], a household-based cluster-randomized double-blind trial that was conducted in Nangapanda, Ende district of Flores Island, Indonesia. After randomization, study subjects received either a single tablet of albendazole (400 mg) or matching placebo (tablets from PT Indopharma Pharmaceutical, Bandung, Indonesia) for 3 consecutive days under direct supervision from the research team members. This treatment regimen was given every 3 months for a total of 4 rounds (maximum of 12 tablets in total), between May 2014 and February 2015.

Although the study was aimed at subjects aged 16 and above, all subjects in the study area, except children below 2 years of age and pregnant women, were included in the trial to avoid cross-contamination between household members. Subjects aged 16 and above underwent clinical and laboratory examination. Written informed consent was obtained from participants prior to the study. The study was approved by the ethics committee of the Faculty of Medicine, Universitas Indonesia (ref: 549/H2-F1/ETIK/2013), and filed by the ethics committee of

Leiden University Medical Center, the Netherlands. The trial is registered as a clinical trial (Reference ISRCTN75636394).

Study Population

Randomization for the total study was based on 752 households comprising 3698 individuals, resulting in 1825 (377 houses) and 1741 (375 houses) subjects in the placebo and albendazole group, respectively (Supplementary Figure 1). An additional household randomization was performed on the 2406 subjects aged 16 and above, in order to study immune mechanisms in more detail [29]. For this subgroup, we aimed to select 1 subject per household and stratified by age group (16–36 years, 36–56 years, and >56 years) to ensure that sufficient numbers of all groups were represented. This resulted in a total of 300 subjects who were included for immunological studies (152 subjects on placebo and 148 subjects in albendazole group) and randomly selected, paired samples from 195 subjects were subsequently used for flow cytometric analysis.

We also collected venous blood of 9 healthy volunteers that had not been exposed to helminth infections, hereafter referred to as “Europeans”. We used the whole blood samples for flow cytometric analysis to assess granulocyte phenotype and response in naive subjects.

Parasitological Examination

DNA isolation from frozen stool samples was performed as described elsewhere [30, 31]. Multiplex real-time polymerase chain reaction (PCR) was performed to simultaneously detect the presence of hookworm (*Ancylostoma duodenale*, *Necator americanus*), *Ascaris lumbricoides*, *Trichuris trichiura*, and *Strongyloides stercoralis*, using a method described previously [30]. Stool samples were considered positive by PCR when cycle threshold (Ct) values were <50. Because the prevalence of *S. stercoralis* at baseline was very low (1.4%; 4/284), this species was not included in the analysis.

Sample Collection

Blood samples were processed as previously described [29, 32]. Briefly, 200 μ L of heparinized blood was preincubated for 5 minutes in a 37°C water bath, followed by a 5-minute stimulation with fMLF 10^{-5} M (Sigma, Saint Louis, MO) or eotaxin (10^{-7} M; R&D systems, Abingdon, UK) or left unstimulated. While both Indonesian and European blood samples were stimulated with fMLF, stimulation with eotaxin was only performed for Indonesian samples. Subsequently, 4 mL of fluorescence-activated cell sorting (FACS) lysing solution (BD Biosciences) was added for 15 minutes at room temperature, then cells were washed with RPMI 1640 containing 10% heat-inactivated fetal calf serum (FCS) and resuspended in RPMI 1640 containing 10% FCS and 10% dimethyl sulfoxide. Cryovials containing the cell suspension were placed at -80°C for a minimum of 4 hours, followed by storage in liquid nitrogen until analysis.

Flow Cytometry of Granulocyte Surface Markers

While flow cytometric analysis of the samples was randomly divided over multiple measurement days, all samples belonging to 1 individual were thawed, stained, and measured pairwise (baseline and follow-up) on the same day. After thawing, cells were washed in RPMI 1640 containing 10% FCS and resuspended in FACS buffer (phosphate-buffered saline supplemented with 0.5% bovine serum albumin and 2 mM ethylenediaminetetraacetic acid [EDTA]). Cells were counted using microscopy and 500 000 white blood cells were stained for 30 minutes at 4°C with anti-CD35-FITC, anti-CD66b-PerCP/Cy5.5, anti-CD193-PE, anti-CD16-PE/CF594, anti-CD69-PE/Cy5, anti-CD274-PE/Cy7, anti-CD3/CD19/CD20/CD56-APC, anti-CD11b-APC/eF780, anti-CD203c-BV421, anti-CD14-BV510, anti-CD62L-BV605. Antibody details can be found in [Supplementary Table 1](#). For each antibody, a fluorescence-minus-one control sample was included using pooled cells from different subjects. Cells were acquired on a LSR Fortessa flow cytometer (BD Biosciences) and before each measurement a performance run was conducted with cytometer setup and tracking beads (CS&T; BD Biosciences). Data was analyzed in FlowJo software (version 9.9.3) and median fluorescence intensity (MFI) data are displayed. Representative gating schemes to select eosinophil and neutrophils are shown in [Supplementary Figure 2](#). As all cells of each sample were acquired, the absolute numbers of eosinophils and neutrophils that were analyzed differed between samples.

After gating all leukocyte populations (eosinophils, neutrophils, basophils, monocytes, and lymphocytes), percentages of eosinophils and neutrophils were calculated relative to the total amount of white blood cells. The absolute eosinophil count reflects the number of eosinophils in 200 µL blood, and was calculated using the proportion of eosinophils and the white blood cell count after thawing.

As described previously [32], the detection of CD62L on eosinophils was impaired as a result of fixation and this marker was therefore not included in the analysis as an activation marker for eosinophils.

Serum Eosinophil Granule Proteins

The serum concentrations of eosinophil granule proteins (MBP, ECP, EDN, and EPO) were measured in a suspension array assay in multiplex as previously described [33]. As the levels of EPO were below the limit of detection of 6 ng/mL in every sample, this protein was excluded from analysis. Eosinophil granule proteins were measured in the total subgroup selected for immunological studies (300 and 258 subjects at baseline and follow-up, respectively). In 5/558 samples, 1 of the proteins could not be detected while in 1/558 samples, neither MBP, ECP, nor EDN could be detected.

Statistical Analysis

For continuous variables, normally distributed data were presented as mean and standard deviation, while non-normally

distributed data (eosinophil count, total IgE, eosinophil granule proteins, and eosinophil activation markers) were presented as geometric mean (geomean) and 95% confidence interval (CI), and log-transformed for analyses. Categorical data, such as infection prevalence, were expressed as proportions. Comparisons between STH-infected and uninfected subjects at baseline were performed with Student *t* test. Comparisons between Indonesian STH-infected, Indonesian uninfected, and European subjects were performed with ANOVA followed by Tukey multiple comparisons test. ANOVA followed by a Dunnett multiple comparison test was used to test granulocyte counts after stratifying subjects by helminth species. To determine the relationship between serum levels of eosinophil granular proteins and eosinophil counts Spearman rank correlation was used. Paired *t* tests were performed to assess the responsiveness of granulocytes to eotaxin or fMLF. *P* values < .05 were considered statistically significant.

The effect of anthelmintic treatment on eosinophil counts, eosinophil granule proteins, and eosinophil activation markers was assessed using an intention-to-treat approach, applying mixed models to account for the correlation within households. Two random effects were used: to model clustering within households a random household specific intercept was used and to model correlation within subjects random subject-specific intercept was used. Parameter estimates for treatment effect and 95% CIs were reported. The reported *P* values were obtained using a likelihood ratio test comparing the model with and without the treatment effect. For the binary outcome (helminth infection status), a logistic model was used with random household effects and random subject effects. All models were fitted using the lme4 package (R software).

RESULTS

Study Population

At baseline, 300 subjects were included for immunological studies (152 and 148 subjects in the placebo and the albendazole group, respectively; [Supplementary Figure 1](#)). The loss to follow-up was 14%, which was mainly due to movement out of the village. Baseline characteristics of the study participants are shown in [Table 1](#), while details of a subset of the study population (*n* = 195) used to study granulocyte activation markers by flow cytometry can be found in [Supplementary Table 1](#).

At baseline, 59.2% (168/284) of the individuals were infected with 1 or more helminth species, with hookworm infection being the most prevalent. In all subjects treated with albendazole in the SugarSPIN trial, the prevalence of helminth infection was 55.4% before and 11.3% after treatment [30]. Similar to this result, we observed that albendazole treatment reduced the percentage of subjects with any helminth from 55.9% (80/143) to 9.2% (11/120) in the albendazole arm versus 62.4% (88/141) to 51.2% (62/121) in the placebo arm (*P* < .0001). The highest

Table 1. Baseline Characteristics of the Study Population

Characteristic	Placebo Group		Albendazole Group	
	n	Value	n	Value
Age, mean, y (SD)	151	46.7 (13.4)	148	46.2 (16.2)
Sex, female, n (%)	151	100 (66.2)	148	86 (58.1)
BMI, kg/m ² , mean (SD)	149	23.1 (4.2)	147	22.5 (4.2)
Total IgE, IU/mL, GM (95% CI)	150	663 (506–870)	148	672 (514–878)
Eosinophil count, ^a GM (95% CI)	148	5.5 (4.9–6.2)	146	6.1 (5.5–6.8)
MBP, ng/mL, GM (95% CI)	150	978 (859–1154)	147	969 (830–1132)
ECP, ng/mL, GM (95% CI)	150	908 (756–1124)	147	935 (786–1111)
EDN, ng/mL, GM (95% CI)	149	346 (295–408)	147	380 (326–442)
Helminth infection by PCR, n (%)	141	88 (62.4)	143	80 (55.9)
<i>Ascaris lumbricoides</i>	141	36 (25.5)	143	22 (15.4)
Hookworm	141	62 (44.0)	143	53 (37.1)
<i>Trichuris trichiura</i>	141	50 (35.5)	143	36 (25.2)

Abbreviations: BMI, body mass index; ECP, eosinophil cationic protein; EDN, eosinophil-derived neurotoxin; GM, geometric mean; IgE, immunoglobulin E; MBP, major basic protein; PCR, polymerase chain reaction; SD, standard deviation.

^aDetermined by using a Giemsa-stained peripheral thin blood smear.

reduction was seen for hookworm, followed by *A. lumbricoides* and *T. trichiura* infection (Supplementary Figure 3).

Granulocyte Counts in Peripheral Blood

At baseline, the frequency of eosinophils in whole blood was significantly higher in infected subjects compared to noninfected subjects: STH-positive geomean 7.0% (95% CI, 6.3%–7.8%) versus STH-negative 5.5% (95% CI, 4.7%–6.5%), $P = .01$ (Figure 1A). Irrespective of coinfection with other helminths, subjects infected with hookworm showed the highest eosinophil frequencies (7.9%; 95% CI, 6.9%–8.9%) (Figure 1A). As observed in the whole SugarSPIN trial [34], anthelmintic treatment effectively reduced eosinophil frequencies, especially in those infected with helminths at baseline; the estimated treatment effect was -0.187 (95% CI, -0.258 to -0.117 ; $P = .01$; Figure 1C). Neutrophil counts did not differ between uninfected and infected subjects at baseline ($P = .59$; Figure 1B). Interestingly, albendazole treatment significantly increased the frequency of neutrophils in peripheral blood in those who were infected with helminths at baseline (0.041 ; 0.017 – 0.066 ; $P < .01$; Figure 1D). While Europeans exhibited significantly lower eosinophil frequencies (geomean 1.9%; 95% CI, 0.9%–3.7%) compared to Indonesians, irrespective of current helminth infections, similar frequencies of neutrophils were observed (geomean 53%; 95% CI, 45%–62%).

Eosinophil Activation Status and Responsiveness

At baseline, the intensity of the eosinophil activation markers CD11b, CD35, CD66b, and CD69 was similar in STH-infected and uninfected subjects (Table 2). Albendazole treatment did not influence the expression of these markers (Table 3). Neither at community level, nor when analyzing subjects with helminth infection as baseline. The comparison with

Europeans revealed a lower intensity of CD35 in Indonesian subjects, both STH infected and uninfected, while other markers did not differ (Table 2).

Whole blood stimulated with eotaxin or fMLF was used to assess the responsiveness of eosinophils. The intensity of CD11b, CD35, CD66b, and CD69 on eotaxin- or fMLF-stimulated eosinophils did not differ between uninfected subjects and those infected with helminths at baseline (Supplementary Figure 4A, B). Moreover, albendazole treatment did not affect the responsiveness (data not shown). Interestingly, not all individuals responded to eotaxin or fMLF by upregulating the activation markers. In half of the subjects, there was an increase in the MFI of the activation markers whereas in the other half the MFI of markers decreased after stimulation (Supplementary Figure 4C, D). Of note, in those who had a low intensity of markers before stimulation, the expression of the markers went up whereas the opposite was seen in subjects who had a high marker expression (Supplementary Figure 4C, D). However, this observation could not be associated with the infection status, because in both infected and uninfected subjects the same was seen. In Europeans, most subjects responded to fMLF by upregulating the activation markers, also reflected in a stronger upregulation compared to Indonesians (Supplementary Figure 4B).

Neutrophil Activation Status and Responsiveness

We found no difference in the expression levels of neutrophil activation markers (CD11b, CD35, CD66b, and CD62L) between STH-infected and uninfected subjects at baseline (Table 2), and treatment did not alter the intensity of these markers (Table 3). When compared to Europeans, levels of both CD11b and CD62L were lower in Indonesians, irrespective of their current infection status (Table 2). Although neutrophils strongly responded to fMLF by upregulating CD11b, CD35, and CD66b, while shedding CD62L, the responsiveness was similar in all subjects, irrespective of their helminth infection status (Supplementary Figure 5). Albendazole treatment did not affect neutrophil responsiveness (data not shown). When neutrophils in Europeans were considered, the responsiveness was more marked compared to Indonesians (Supplementary Figure 5).

Eosinophil Granule Proteins

Serum levels of MBP, ECP, and EDN were similar in STH-infected and uninfected subjects at baseline: MBP, STH-positive geomean 979 ng/mL (95% CI, 864–1156) versus STH-negative 910 ng/mL (95% CI, 766–1063), $P = .52$; ECP, STH-positive 892 ng/mL (95% CI, 748–1077) versus STH-negative 920 ng/mL (95% CI, 764–1129), $P = .82$; EDN, STH-positive 362 ng/mL (95% CI, 313–423) versus STH-negative 353 ng/mL (95% CI, 297–419, $P = .83$ (Figure 2A). No relationship was found between protein concentrations and helminth species or the total number of helminth species a subject was

Figure 1. Granulocyte frequencies. Percentage of eosinophils (A) and neutrophils (B) relative to the total number of WBC in STH- and STH+ subjects (left) and in STH- and AI+, Hw+, and Tt+ subjects (right). Counts at baseline are shown with geometric means and 95% CIs (STH-, $n = 73$; STH+, $n = 118$; AI+, $n = 42$; Hw+, $n = 81$; Tt+, $n = 61$). The effect of anthelmintic treatment on eosinophil (C) and neutrophil (D) counts is displayed with 95% CIs ($n = 195$). Differences between STH- and STH+ subjects were tested with Student t test. Differences between STH-, AI+, Hw+, and Tt+ subjects were tested with ANOVA followed by a Dunnett multiple comparison test. Treatment effect was assessed using mixed models (see Methods). * $P < .05$; ** $P < .01$. Abbreviations: CI, confidence interval; NS, not significant; STH, soil-transmitted helminths; AI, *Ascaris lumbricoides*; Hw, hookworm; Tt, *Trichuris trichiura*; WBC, white blood cells.

Table 2. Expression of Granulocyte Activation Markers at Baseline

Marker	MFI (95% CI) ^a		
	STH Negative ($n = 73$)	STH Positive ($n = 118$)	European ($n = 9$)
Eosinophils			
CD11b	1444 (1337–1559)	1376 (1297–1459)	1700 (1551–1864)
CD35	3269 (3144–3435)	3254 (3150–3360)	3915 (3688–4155) ^{b,c}
CD66b	2100 (2031–2172)	2055 (2004–2108)	2046 (1825–2295)
CD69	783 (735–834)	772 (737–809)	677 (632–725)
Neutrophils			
CD11b	1151 (1107–1196)	1172 (1141–1203)	1387 (1238–1554) ^{b,c}
CD35	1571 (1457–1695)	1618 (1519–1722)	1413 (1101–1816)
CD66b	581 (553–609)	592 (568–617)	590 (532–654)
CD62L	748 (676–827)	788 (726–856)	1358 (1262–1462) ^{b,c}

Abbreviation: STH, soil-transmitted helminths.

^aGeometric mean of median fluorescence intensity (MFI) and corresponding 95% confidence intervals (CI) are shown.

^b $P < .05$ analyzed using ANOVA Tukey statistical test for comparison with Indonesian STH-negative subjects.

^c $P < .05$ analyzed using ANOVA Tukey statistical test for comparison with Indonesian STH-positive subjects.

infected with (data not shown). Levels of EDN correlated with absolute eosinophil counts at baseline ($r = 0.54$, P value $\leq .01$); however, the correlation coefficient for MBP, although statistically significant, was weak (MBP: $r = 0.27$, $P \leq .01$) and when considering ECP no correlation could be found with eosinophil counts (ECP: $r = 0.03$, $P = .69$) (Supplementary Figure 6). Albendazole treatment decreased the level of MBP (estimated treatment effect -0.070 ; 95% CI, -0.124 to -0.015 ; $P = .01$) and EDN (estimated treatment effect -0.060 ; 95% CI, -0.121 to 0.0002 ; $P = .05$), whereas the level of ECP did not change (estimated treatment effect 0.006 ; 95% CI, -0.078 to 0.090 ; $P = .93$) at community level (Figure 2B). When analyzing those infected with helminths at baseline, EDN levels significantly decreased after treatment (estimated treatment effect -0.093 ; 95% CI, -0.172 to -0.013 ; $P = .02$).

DISCUSSION

Eosinophil numbers are associated with helminth infections. We hypothesized that not only eosinophil numbers but also

Table 3. The Effect of Anthelmintic Treatment on Granulocyte Activation Markers

Marker	Estimated Treatment Effect (95% CI), <i>P</i> Value		
	All (n = 195)	STH Negative (n = 73)	STH Positive (n = 118)
Eosinophils			
CD11b	0.024 (−0.010 to 0.058), <i>P</i> = .18	0.012 (−0.045 to 0.069), <i>P</i> = .69	0.039 (−0.005 to 0.082), <i>P</i> = .09
CD35	0.009 (−0.006 to 0.024), <i>P</i> = .23	0.008 (−0.018 to 0.034), <i>P</i> = .54	0.015 (−0.004 to 0.034), <i>P</i> = .13
CD66b	0.003 (−0.008 to 0.014), <i>P</i> = .55	0.004 (−0.016 to 0.024), <i>P</i> = .73	0.007 (−0.007 to 0.020), <i>P</i> = .32
CD69	−0.016 (−0.038 to 0.007), <i>P</i> = .19	−0.029 (−0.067 to 0.009), <i>P</i> = .14	0.003 (−0.026 to 0.031), <i>P</i> = .86
Neutrophils			
CD11b	0.003 (−0.018 to 0.023), <i>P</i> = .81	0.021 (−0.014 to 0.055), <i>P</i> = .25	−0.007 (−0.032 to 0.018), <i>P</i> = .60
CD35	−0.010 (−0.041 to 0.021), <i>P</i> = .53	0.001 (−0.058 to 0.061), <i>P</i> = .96	−0.010 (−0.045 to 0.025), <i>P</i> = .59
CD66b	0.015 (−0.002 to 0.032), <i>P</i> = .09	0.023 (−0.006 to 0.052), <i>P</i> = .12	0.010 (−0.012 to 0.032), <i>P</i> = .39
CD62L	0.029 (−0.029 to 0.087), <i>P</i> = .33	0.053 (−0.041 to 0.146), <i>P</i> = .27	−0.009 (−0.082 to 0.065), <i>P</i> = .82

Treatment effect was assessed using mixed models (see Methods). *P* values were obtained using a likelihood ratio test comparing the model with and without the treatment effect.

Abbreviations: CI, confidence interval; STH, soil-transmitted helminths.

their activation status would be affected by the presence of helminths. As a measure of activation, a range of activation markers in peripheral blood eosinophils and neutrophils were assessed, as well as the responsiveness to stimulation. In addition, circulating levels of eosinophil granule proteins were measured as a marker for the activation status of eosinophils, not only in blood but also in tissues. This study was nested within

a cluster-randomized, double-blind placebo-controlled trial, conducted in a rural area in Indonesia [29]. To our knowledge, this is the first placebo-controlled trial studying the effect of helminth infections on granulocyte activation and derives strength from its design and large sample size.

Although the number of eosinophils was higher in STH-infected compared to uninfected subjects and decreased

Figure 2. Eosinophil granule proteins. Major basic protein (MBP), eosinophil cationic protein (ECP), and eosinophil derived neurotoxin (EDN) concentrations in serum at baseline (A) and the effect of albendazole treatment (B) are shown. A, Lines represent geometric means and 95% CIs (STH−, n = 116; STH+, n = 168). B, The effect of anthelmintic treatment is displayed with 95% CIs (n = 299). Differences between STH− and STH+ subjects were tested with Student *t* test. Treatment effect was assessed using mixed models (see Methods). Abbreviations: CI, confidence interval; NS, not significant; STH, soil-transmitted helminths.

significantly after albendazole treatment, the intensities of eosinophil, as well as neutrophil, activation markers were not affected by helminths and did not change upon anthelmintic treatment. This is in contrast to what has been reported [11, 13–15, 25–28]. Previously, Mawhorter et al [13] showed an elevated percentage of CD69, CD66, and CD81 positive eosinophils in 18 subjects recruited in the United States, infected with 1 or more species of 7 helminths, and found CD66 to be decreased in the 5 subjects that were followed after short-term anthelmintic treatment. In a study conducted in Brazil, the observation that the frequency of CD23⁺ eosinophils increased while that of CD62L⁺ cells decreased in subjects infected with *Schistosoma mansoni*, led to the conclusion that eosinophils were chronically activated during infection [15]. However, this conflicted with a lower frequency of CD69⁺ eosinophils, indicating little early activation of eosinophils [15]. In another study in Brazil, Fujiwara et al [14] demonstrated a highly activated state of eosinophils in subjects infected with hookworms compared to uninfected individuals [14]. None of these studies, in contrast to ours, included uninfected subjects from the endemic regions. Moreover, they included a relatively small number of study subjects (varying from 23 to 35 individuals) and, perhaps more importantly, the antibody staining was directly performed on fresh blood. As we were limited by the infrastructure at the field study site with no direct access to a flow cytometer, we developed a method to analyze granulocyte activation markers in cryopreserved, fixed whole blood [32]. As previously described, it was observed that marker intensities varied when comparing fresh and fixed granulocytes, most likely due to intracellular staining and increased eosinophil autofluorescence as a consequence of fixation [32]. However, we showed that the responsiveness to stimuli could still be clearly measured after fixation. Nevertheless, it is possible that the use of fresh cells allows smaller differences to be detected.

By including European subjects, we could compare the results with naive eosinophils and neutrophils from individuals with lower exposure to microorganisms and helminths. The eosinophils from Indonesians had a lower expression of the activation marker CD35 and a lower responsiveness to fMLF. With respect to neutrophils, there was an interesting observation that both CD62L and CD11b showed a lower expression in Indonesians. While lower CD11b on neutrophils from Indonesians would indicate a lower activation status of these cells, the lower expression of CD62L, which is shed by activated neutrophils, would suggest a higher activation status of neutrophils in Indonesians, contradicting the CD11b data. However, the loss of CD62L has also been associated with aged neutrophils [35], and therefore it is possible that in Indonesia the higher exposure of the granulocytes to microbes or inflammation results in more aged granulocytes with lower responsiveness. Indeed, this is supported by the lower activation of neutrophils from Indonesian subjects by fMLF compared to the response of neutrophils from Europeans. However, future studies are needed to clarify this further.

Whereas the expression of activation markers was assessed in circulating eosinophils, mature eosinophils are predominantly tissue-dwelling cells and serum levels of eosinophil granule proteins are thought to be an indirect measure of degranulation in the tissues. MBP, stored in the core of secondary granules, is the most abundant protein, whereas EDN and ECP, also known as RNase2 and RNase3, respectively, both have ribonuclease activity and can be found in the granule matrix [1]. In contrast to our hypothesis, we observed no differences in the levels of eosinophil granule proteins between helminth-infected and uninfected subjects. It should be noted that the study area was highly endemic for STH infections [36] and perhaps exposure to an environment contaminated with parasite eggs or infective larvae can lead to altered eosinophil homeostasis and maturity/activation, thereby masking the potential difference between currently infected and uninfected subjects.

Elevated eosinophil cationic protein levels have previously been described, not only in subjects infected with STH but also with filarial parasites and with schistosomes [25–28, 37]. Whereas most studies had a cross-sectional design, 2 reports described a significant decline in granular protein levels in subjects infected with *S. mansoni* or *S. stercoralis* after anthelmintic treatment, indicating a decrease in eosinophil degranulation [25, 28]. In our study, albendazole treatment significantly decreased EDN levels in subjects that were infected at baseline, whereas the levels of MBP and ECP did not change. Out of the 3 proteins, EDN also showed the strongest correlation with the number of eosinophils at baseline and therefore its decrease is likely to reflect the decrease in eosinophil numbers after treatment.

The aim of this study was to investigate the effect of soil-transmitted helminths on granulocyte activation. We conclude that helminths affect eosinophil numbers in the circulation, but the activation status and responsiveness of these cells is similar between infected and uninfected subjects, and was not influenced by anthelmintic treatment. The same applies to neutrophils. However, this study should be repeated in an endemic setting with access to a flow cytometer that would allow the analysis of fresh granulocytes to assess activation of these cells, as fixing cells might not allow subtle differences to be detected between helminth infected and uninfected or before and after treatment.

Supplementary Data

Supplementary materials are available at *The Journal of Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

Acknowledgments. The authors thank all study participants and field workers in Nangapanda, Ende, Flores, Indonesia. The

authors also thank Samatha Bandapalle for performing the eosinophil granule protein suspension array assay at the Laboratory of Parasitic Diseases at the National Institutes of Health, Bethesda, MD, and Dr E. F. Knol (Laboratory of Translational Immunology, Dept. of Dermatology and Allergology, University Medical Center Utrecht) for his initial help with the study.

Financial support. This work was supported by The Royal Netherlands Academy of Arts and Science (grant number Ref 57-SPIN3-JRP).

Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Ravin KA, Loy M. The eosinophil in infection. *Clin Rev Allergy Immunol* **2016**; 50:214–27.
2. McLaren DJ, McKean JR, Olsson I, Venges P, Kay AB. Morphological studies on the killing of schistosomula of *Schistosoma mansoni* by human eosinophil and neutrophil cationic proteins in vitro. *Parasite Immunol* **1981**; 3:359–73.
3. Ackerman SJ, Gleich GJ, Loegering DA, Richardson BA, Butterworth AE. Comparative toxicity of purified human eosinophil granule cationic proteins for schistosomula of *Schistosoma mansoni*. *Am J Trop Med Hyg* **1985**; 34:735–45.
4. Hamann KJ, Barker RL, Loegering DA, Gleich GJ. Comparative toxicity of purified human eosinophil granule proteins for newborn larvae of *Trichinella spiralis*. *J Parasitol* **1987**; 73:523–9.
5. Hamann KJ, Gleich GJ, Checkel JL, Loegering DA, McCall JW, Barker RL. In vitro killing of microfilariae of *Brugia pahangi* and *Brugia malayi* by eosinophil granule proteins. *J Immunol* **1990**; 144:3166–73.
6. Klion AD, Nutman TB. The role of eosinophils in host defense against helminth parasites. *J Allergy Clin Immunol* **2004**; 113:30–7.
7. Huang L, Gebreselassie NG, Gagliardo LF, et al. Eosinophil-derived IL-10 supports chronic nematode infection. *J Immunol* **2014**; 193:4178–87.
8. Huang L, Beiting DP, Gebreselassie NG, et al. Eosinophils and IL-4 support nematode growth coincident with an innate response to tissue injury. *PLoS Pathog* **2015**; 11:e1005347.
9. Weller PF, Spencer LA. Functions of tissue-resident eosinophils. *Nat Rev Immunol* **2017**; 17:746–60.
10. Wu D, Molofsky AB, Liang HE, et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. *Science* **2011**; 332:243–7.
11. Gazzinelli-Guimaraes PH, Bonne-Annee S, Fujiwara RT, Santiago HC, Nutman TB. Allergic sensitization underlies hyperreactive antigen-specific CD4+ T cell responses in co-incident filarial infection. *J Immunol* **2016**; 197:2772–9.
12. Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. *Nat Rev Immunol* **2013**; 13:9–22.
13. Mawhorter SD, Stephany DA, Ottesen EA, Nutman TB. Identification of surface molecules associated with physiologic activation of eosinophils. Application of whole-blood flow cytometry to eosinophils. *J Immunol* **1996**; 156:4851–8.
14. Fujiwara RT, Cançado GG, Freitas PA, et al. Necator americanus infection: a possible cause of altered dendritic cell differentiation and eosinophil profile in chronically infected individuals. *PLoS Negl Trop Dis* **2009**; 3:e399.
15. Silveira-Lemos D, Teixeira-Carvalho A, Martins-Filho OA, Oliveira LF, Corrêa-Oliveira R. High expression of co-stimulatory and adhesion molecules are observed on eosinophils during human *Schistosoma mansoni* infection. *Mem Inst Oswaldo Cruz* **2006**; 101 (Suppl 1):345–51.
16. Berends C, Hoekstra MO, Dijkhuizen B, de Monchy JG, Gerritsen J, Kauffman HF. Expression of CD35 (CR1) and CD11b (CR3) on circulating neutrophils and eosinophils from allergic asthmatic children. *Clin Exp Allergy* **1993**; 23:926–33.
17. in 't Veen JC, Grootendorst DC, Bel EH, et al. CD11b and L-selectin expression on eosinophils and neutrophils in blood and induced sputum of patients with asthma compared with normal subjects. *Clin Exp Allergy* **1998**; 28:606–15.
18. Mann BS, Chung KF. Blood neutrophil activation markers in severe asthma: lack of inhibition by prednisolone therapy. *Respir Res* **2006**; 7:59.
19. Metcalfe DD, Pawankar R, Ackerman SJ, et al. Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases. *World Allergy Organ J* **2016**; 9:7.
20. Santamaria LF, Palacios JM, Beleta J. Inhibition of eotaxin-mediated human eosinophil activation and migration by the selective cyclic nucleotide phosphodiesterase type 4 inhibitor rolipram. *Br J Pharmacol* **1997**; 121:1150–4.
21. Tenschler K, Metzner B, Schöpf E, Norgauer J, Czech W. Recombinant human eotaxin induces oxygen radical production, Ca(2+)-mobilization, actin reorganization, and CD11b upregulation in human eosinophils via a pertussis toxin-sensitive heterotrimeric guanine nucleotide-binding protein. *Blood* **1996**; 88:3195–9.
22. O'Connell AE, Hess JA, Santiago GA, et al. Major basic protein from eosinophils and myeloperoxidase from neutrophils are required for protective immunity to *Strongyloides stercoralis* in mice. *Infect Immun* **2011**; 79:2770–8.
23. Buys J, Wever R, Ruitenberg EJ. Myeloperoxidase is more efficient than eosinophil peroxidase in the in vitro killing of newborn larvae of *Trichinella spiralis*. *Immunology* **1984**; 51:601–7.

24. Jong EC, Mahmoud AA, Klebanoff SJ. Peroxidase-mediated toxicity to schistosomes of *Schistosoma mansoni*. *J Immunol* **1981**; 126:468–71.
25. Rajamanickam A, Munisankar S, Bhootra Y, Dolla CK, Nutman TB, Babu S. Elevated systemic levels of eosinophil, neutrophil, and mast cell granular proteins in *Strongyloides stercoralis* infection that diminish following treatment. *Front Immunol* **2018**; 9:207.
26. Tischendorf FW, Brattig NW, Büttner DW, Pieper A, Lintzel M. Serum levels of eosinophil cationic protein, eosinophil-derived neurotoxin and myeloperoxidase in infections with filariae and schistosomes. *Acta Trop* **1996**; 62:171–82.
27. Tischendorf FW, Brattig NW, Lintzel M, et al. Eosinophil granule proteins in serum and urine of patients with helminth infections and atopic dermatitis. *Trop Med Int Health* **2000**; 5:898–905.
28. Reimert CM, Tukahebwa EM, Kabatereine NB, Dunne DW, Vennervald BJ. Assessment of *Schistosoma mansoni* induced intestinal inflammation by means of eosinophil cationic protein, eosinophil protein X and myeloperoxidase before and after treatment with praziquantel. *Acta Trop* **2008**; 105:253–9.
29. Tahapary DL, de Ruiter K, Martin I, et al. Helminth infections and type 2 diabetes: a cluster-randomized placebo controlled SUGARSPIN trial in Nangapanda, Flores, Indonesia. *BMC Infect Dis* **2015**; 15:133.
30. Tahapary DL, de Ruiter K, Martin I, et al. Effect of anthelmintic treatment on insulin resistance: a cluster-randomized, placebo-controlled trial in Indonesia. *Clin Infect Dis* **2017**; 65:764–71.
31. Kaisar MMM, Brienens EAT, Djuardi Y, et al. Improved diagnosis of *Trichuris trichiura* by using a bead-beating procedure on ethanol preserved stool samples prior to DNA isolation and the performance of multiplex real-time PCR for intestinal parasites. *Parasitology* **2017**; 144:965–74.
32. de Ruiter K, van Staveren S, Hilvering B, et al. A field-applicable method for flow cytometric analysis of granulocyte activation: Cryopreservation of fixed granulocytes. *Cytometry A* **2018**; 93:540–7.
33. Makiya MA, Herrick JA, Khoury P, Prussin CP, Nutman TB, Klion AD. Development of a suspension array assay in multiplex for the simultaneous measurement of serum levels of four eosinophil granule proteins. *J Immunol Methods* **2014**; 411:11–22.
34. de Ruiter K, Tahapary DL, Sartono E, et al. Helminths, hygiene hypothesis and type 2 diabetes. *Parasite Immunol* **2017**; 39(5).
35. Van Eeden SF, Bicknell S, Walker BA, Hogg JC. Polymorphonuclear leukocytes L-selectin expression decreases as they age in circulation. *Am J Physiol* **1997**; 272:H401–8.
36. Wiria AE, Hamid F, Wammes LJ, et al. The effect of three-monthly albendazole treatment on malarial parasitemia and allergy: a household-based cluster-randomized, double-blind, placebo-controlled trial. *PLoS One* **2013**; 8:e57899.
37. Herrick JA, Metenou S, Makiya MA, et al. Eosinophil-associated processes underlie differences in clinical presentation of loiasis between temporary residents and those indigenous to Loa-endemic areas. *Clin Infect Dis* **2015**; 60:55–63.